Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor- or intermediate-risk cytogenetics.Patients (N = 485) age ≥ 65 years were randomly assigned...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur
Formato: Artigo
Lenguaje:inglés
Publicado: 2012
Acceso en línea:https://doi.org/10.1200/jco.2011.38.9429
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2011.38.9429?role=tab
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doi.org/10.1200/jco.2011.38.9429
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2011.38.9429?role=tab

Ejemplares similares